Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
71 participants
INTERVENTIONAL
2025-08-15
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
Participants will receive aleniglipron or placebo administered orally.
aleniglipron or placebo
Drug: aleniglipron administered orally Drug: placebo administered orally
Cohort 2
Participants will receive aleniglipron or placebo administered orally.
aleniglipron or placebo
Drug: aleniglipron administered orally Drug: placebo administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
aleniglipron or placebo
Drug: aleniglipron administered orally Drug: placebo administered orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants age ≥18 years and \<80 years, with BMI ≥30 kg/m2
* Screening HbA1c \<6.5 %
Exclusion Criteria
* Self-reported change in body weight \>5% within 3 months before Screening
* Have a body weight, height, and/or width that prohibits the ability to obtain accurate measurements according to the DXA study specific manual that allows hemi-scan
* Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed \>1 year prior to screening)
* Have obesity induced by other endocrine disorders (such as Cushing's syndrome, Prader-Willi syndrome, or melanocortin 4 receptor deficiency)
18 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Phoenix, Arizona, United States
Research Site
Chicago, Illinois, United States
Research Site
Richfield, Minnesota, United States
Research Site
City of Saint Peters, Missouri, United States
Research Site
Rochester, New York, United States
Research Site
Wilmington, North Carolina, United States
Research Site
Norman, Oklahoma, United States
Research Site
Moncks Corner, South Carolina, United States
Research Site
North Charleston, South Carolina, United States
Research Site
Austin, Texas, United States
Research Site
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GSBR-1290-16
Identifier Type: -
Identifier Source: org_study_id